Effects of long-term treatment with the MAO-A inhibitor moclobemide on sleep EEG and nocturnal hormonal secretion in normal men.
Sleep EEG, nocturnal penile tumescence (NPT) and nocturnal hormone secretion were studied in four normal males during placebo, under up to 300 mg per day of moclobemide, the short-acting and reversible inhibitor of monoamine oxidase (type A), and after withdrawal. Under moclobemide, REM sleep was slightly suppressed. Drug cessation was followed by REM rebound. In contrast to REM sleep, NPT was not affected by the drug. The nocturnal cortisol concentration was elevated under moclobemide and this effect persisted after withdrawal. No influences on growth hormone, prolactin, testosterone, luteinizing hormone or follicle-stimulating hormone were found.
Steiger
A
A
Department of Psychiatry, University of Mainz, Germany.
Benkert
O
O
Holsboer
F
F
D000328:Adult; D001549:Benzamides / Q000009:adverse effects / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004569:Electroencephalography / Q000187:drug effects; D005640:Follicle Stimulating Hormone / Q000097:blood; D013006:Growth Hormone / Q000097:blood; D006728:Hormones / Q000097:blood*; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D020912:Moclobemide; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects / Q000494:pharmacology*; D010410:Penile Erection / Q000187:drug effects; D017286:Polysomnography / Q000187:drug effects*; D011388:Prolactin / Q000097:blood; D012894:Sleep Stages / Q000187:drug effects*; D012895:Sleep, REM / Q000187:drug effects; D013375:Substance Withdrawal Syndrome / Q000097:blood; D013739:Testosterone / Q000097:blood
D001549:Benzamides; D006728:Hormones; D008996:Monoamine Oxidase Inhibitors; D013739:Testosterone; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D013006:Growth Hormone; D020912:Moclobemide; D006854:Hydrocortisone